CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$48.92 USD
+0.63 (1.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $48.99 +0.07 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.92 USD
+0.63 (1.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $48.99 +0.07 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Zacks News
Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) Q2 earnings call, investors focus will likely be on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $55.44 in the latest trading session, marking a -0.14% move from the prior day.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $57.75, marking a -0.81% move from the previous day.
Vertex (VRTX) Gets Nod in EU for Orkambi Expanded Indication
by Zacks Equity Research
Vertex's (VRTX) Orkambi gets approval from the European Commission in the EU for the treatment of cystic fibrosis in patients (aged 1 to <2 years) who have two copies of the F508del mutation.
CRISPR (CRSP) Shares Rise 24% in the Last Quarter: Here's Why
by Zacks Equity Research
Shares of CRISPR (CRSP) surge 24% in the last quarter after the company, along with Vertex, provides positive regulatory updates on exa-cel BLAs in SCD and TDT treatment.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $56.25 in the latest trading session, marking a +0.2% move from the prior day.
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $56.23, moving +0.36% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $56.89 in the latest trading session, marking a -1.49% move from the prior day.
FDA Accepts Vertex (VRTX), CRISPR's BLA Filings for Exa-Cel
by Zacks Equity Research
The FDA grants priority review to Vertex (VRTX)/CRISPR's (CRSP) filings for exa-cel in SCD, with a final decision expected in December.
Why Is CRISPR Therapeutics AG (CRSP) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex (VRTX) Stock Poised Well for Growth in 2023: Here's Why
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple clinical milestones are likely to be achieved in 2023 and 2024, both in its CF and non-CF portfolio.
CRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat
by Zacks Equity Research
CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 59.88% and 165.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 0% and 8.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -550% and 72.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.
Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023.
Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.13, moving +0.99% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $51.08 in the latest trading session, marking a -1.79% move from the prior day.
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
by Zacks Equity Research
Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
by Zacks Equity Research
Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.
GSK Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.
VYNE Gains on Preclinical Data for IPF Candidate
by Zacks Equity Research
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.